top of page

Low-cost detection of ALS biomarkers

Dr. Mohtashim Shamsi, Southern Illinois University, finalized his 2-year project with NDR. Shamsi investigated the feasibility of using label-free electrochemical detection methods to detect RAN and NfL in serum for patients with ALS. The proof-of-concept study facilitates a low cost point of care biosensing platform for clinical use. Future development of the graphene-modified low cost multiplexed wax-on-plastic biosensing chips include expanding the repertoire of ALS-associated proteins detected in the serum. The future of this technology is in stratifying patients in ALS studies to facilitate getting the right treatment to the right patient. We congratulate Dr. Shamsi on receiving a grant to continue his work on this important topic.

20 views0 comments

Recent Posts

See All

TVALA Drug Trial

We are happy to announce the first patients are being screened for entry into the clinical trial for our drug TVALA! This Phase 1 study will wrap up in a few months and the Phase 2 will start, it will

Thymosin in the treatment of lung cancer

A new paper authored by Liu and Lu in the Frontiers in Immunology reports the Mechanism and clinical application of thymosin in the treatment of lung cancer. Thymosin is a mixture of peptides obtained

MOLECULAR MECHANISMS OF REDOX REGULATION IN INFLAMMATION

We are hopeful that TVALA will reduce p53 expression in people with ALS. There are two recent publications that give us hope. The first paper is by Maor-Nof et. al. (2022), found in Cell. The found

Comments


Commenting has been turned off.
bottom of page